Update: vildagliptin for the treatment of Type 2 diabetes

被引：23

作者：

Garber, Alan J. ^{[1
]}

Sharma, Morali D. ^{[1
]}

机构：

[1] Baylor Coll Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2008年 / 17卷 / 01期

关键词：

DPP-4; glycemic control; HbA(1c); Type; 2; diabetes; vildagliptin;

D O I：

10.1517/13543784.17.1.105

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Vildagliptin is a selective inhibitor of dipeptidyl peptidase-4, and prevents the rapid degradation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Vildagliptin has been evaluated in > 4800 patients in nine Phase III studies in the range of 24 - 52 weeks in duration: four placebo- or active-controlled monotherapy trials that enrolled drug-naive patients; four add-on studies in which vildagliptin was added to a stable regimen of either metformin, a sulfonylurea, a thiazolidinedione or insulin; and a study in which an initial combination of vildagliptin plus pioglitazone in drug-naive patients was evaluated. Across studies, vildagliptin was effective in reducing HbA(1c) had a low risk of hypoglycemia and was weight-neutral and well tolerated.

引用

页码：105 / 113

页数：9

共 45 条

[1]

Vildagliptin:: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties [J].

Ahrén, B .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (04) :431-442

[2]

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].

Ahrén, B ;

Landin-Olsson, M ;

Jansson, PA ;

Svensson, M ;

Holmes, D ;

Schweizer, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084

[3]

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes [J].

Ahrén, B ;

Gomis, R ;

Standl, E ;

Mills, D ;

Schweizer, A .

DIABETES CARE, 2004, 27 (12) :2874-2880

[4]

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients [J].

Balas, Bogdan ;

Baig, Muhammad R. ;

Watson, Catherine ;

Dunning, Beth E. ;

Ligueros-Saylan, Monica ;

Wang, Yibin ;

He, Yan-Ling ;

Darland, Celia ;

Holst, Jens J. ;

Deacon, Carolyn F. ;

Cusi, Kenneth ;

Mari, Andrea ;

Foley, James E. ;

DeFronzo, Ralph A. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04) :1249-1255

[5]

Barilla D, 2004, DIABETES, V53, pA470

[6]

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [J].

Bosi, Emanuele ;

Camisasca, Riccardo Paolo ;

Collober, Carole ;

Rochotte, Erika ;

Garber, Alan J. .

DIABETES CARE, 2007, 30 (04) :890-895

[7]

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile) [J].

Brandt, I ;

Joossens, J ;

Chen, X ;

Maes, MB ;

Scharpé, S ;

De Meester, I ;

Lambeir, AM .

BIOCHEMICAL PHARMACOLOGY, 2005, 70 (01) :134-143

[8]

Burkey BF, 2006, DIABETOLOGIA, V49, P477

[9]

Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study [J].

Dejager, S. ;

Razac, S. ;

Foley, J. E. ;

Schweizer, A. .

HORMONE AND METABOLIC RESEARCH, 2007, 39 (03) :218-223

[10]

Glucose-dependent insulinotropic polypeptide promotes β-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase [J].

Ehses, JA ;

Casilla, VR ;

Doty, T ;

Pospisilik, JA ;

Winter, KD ;

Demuth, HU ;

Pederson, RA ;

McIntosh, CHS .

ENDOCRINOLOGY, 2003, 144 (10) :4433-4445

← 1 2 3 4 5 →